Anti gp130 mab

Manufactured by R&D Systems

Sourced in United States

Anti-gp130 mAb is a monoclonal antibody that binds to the glycoprotein 130 (gp130) receptor. gp130 is a component of the receptor complexes for various cytokines, including interleukin-6 (IL-6) and oncostatin M. This antibody can be used in research applications to study the function and signaling of the gp130 receptor.

Automatically generated - may contain errors

Lab products found in correlation

Rhil 27, by Thermo Fisher Scientific (1 mentions) Non specific mouse igg, by R&D Systems (1 mentions) Il 27, by R&D Systems (1 mentions) Anti iκbα, by BD (1 mentions) Anti p38 mapk, by BD (1 mentions) Recombinant human il 12, by R&D Systems (1 mentions) Gapdh antibody, by Cell Signaling Technology (1 mentions) Ifn γ, by R&D Systems (1 mentions) Tnf α, by R&D Systems (1 mentions) Anti phospho akt, by BD (1 mentions) Anti akt, by BD (1 mentions) Il 23, by R&D Systems (1 mentions)

Spelling variants of this product

Gp130 (3 citations) Anti-gp130 (2 citations)

2 protocols using anti gp130 mab

Blocking IL-27 and IL-6 Signaling Pathways

Check if the same lab product or an alternative is used in the 5 most similar protocols

Inhibition of IL-27 induced STAT1 and STAT3 phosphorylation were performed using increasing concentration of anti-IL-27Rα mAb 5 μg/mL, 10 μg/mL and 20 μg/mL (clone:191,106, R&D Systems, MN), and anti-gp130 mAb (10 μg/mL, clone:28126, R&D Systems, MN) was used to blocked IL-6 induced STAT3 phpophorylation (Figure S1C and S1F respectively, Table S2 Panel 2 and Panel 3).
For the blockade experiments, PBMCs were pre-incubated with anti-IL-27Rα mAbs (10 μg/mL, clone:191106, R&D Systems, MN) or anti-gp130 mAbs (10 μg/mL, clone:28126, R&D Systems, MN), or a combination of both mAbs for 20 minutes on ice. Cells incubated with non-specific mouse IgG (10μg/mL, clone:20,116, R&D Systems, MN) was used as control. Cell were then stimulated with media and rhIL-27 (10 ng/mL; PeproTech, NJ). Staining for phosphorylated STAT1 and STAT3 was performed as describe above with the panel of mAb described in Table S2, Panel 2 and Panel 3.

Cheng J., Myers T.G., Levinger C., Kumar P., Kumar J., Goshu B.A., Bosque A, & Catalfamo M. (2021). IL-27 induces IFN/STAT1-dependent genes and enhances function of TIGIT+ HIVGag-specific T cells. iScience, 25(1), 103588.

+ Open protocol

+ Expand

Cytokine Signaling Pathway Modulation

Check if the same lab product or an alternative is used in the 5 most similar protocols

Recombinant human IL-12, IL-23, IL-27, TNF-α, and IFN-γ were purchased from R&D Systems (MN, USA). GAPDH antibodies were from Cell Signaling Technology (MA, USA). Mouse anti-TCCR/WXS-1 and anti-gp130 mAb were purchased from R&D Systems (MN, USA). Rabbit anti-IL-27 mAb was purchased from Abcam (HKSP, HK). Mouse anti-phospho-p38 mitogen-activated protein kinase (MAPK), anti-phospho-inhibitor(I)κB-α, anti-phospho-Akt, anti-p38MAPK, anti-IκB-α, and anti-Akt mAb were purchased from BD Biosciences (CA, USA). Janus kinase (JAK) inhibitor AG490, IκB-α phosphorylation inhibitor BAY1167082, phosphatidylinositol 3-OH kinase (PI3K) inhibitor LY294002, p38MAPK inhibitor SB203580, c-Jun N-terminal kinase (JNK) inhibitor SP600125, and extracellular signal-regulated kinase (ERK) inhibitor U0126 were purchased from Calbiochem Corp. (San Diego, CA, USA). In this program, the concentration of DMSO was 0.1% (vol/vol) for all data subsets.

Yin N., Zhang H., Luo X., Ding Y., Xiao X., Liu X., Shan N., Zhang X., Deng Q., Zhuang B, & Qi H. (2014). IL-27 Activates Human Trophoblasts to Express IP-10 and IL-6: Implications in the Immunopathophysiology of Preeclampsia. Mediators of Inflammation, 2014, 926875.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!